hers hims semaglutide & abandons copycat weight-loss drug in face of FDA probe Wegovy maker ends partnership with
Description
A phase 2 trial finds that combining semaglutide with bimagrumab leads to greater weight loss while preserving lean mass, highlighting the importance of body composition in obesity treatment.

Laboratory-grade, third-party tested, lyophilized, and intended for research use only.
Energy returns

Trust and Safety in Your Weight Loss Journey Choosing where to obtain your weight loss medication matters enormously
The plaintiffs allege that drugmaker Novo Nordisk didn't warn them about the risks of taking the medication

Disclaimer: These statements have not been evaluated by the Food and Drug Administration